Trials / Withdrawn
WithdrawnNCT04994002
A Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults With Complex Lymphatic Malformations
A Phase 1b, Open-Label, Pharmacokinetic, Pharmacodynamic, Safety and Tolerability Study of CERC-006 in Adults (Aged 18-31 Years) With Complex Lymphatic Malformations
- Status
- Withdrawn
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Avalo Therapeutics, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 31 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to evaluate the safety and tolerability of CERC-006 in adults (aged 18-31 years) with active, moderate to severe complex lymphatic malformations.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | CERC-006 | Oral solution |
Timeline
- Start date
- 2021-09-03
- Primary completion
- 2022-06-01
- Completion
- 2022-06-01
- First posted
- 2021-08-06
- Last updated
- 2022-03-22
Locations
3 sites across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04994002. Inclusion in this directory is not an endorsement.